Robert Ljoljo at the digital Business Conference Portorož on Novartis’ successful response to the pandemic

12. 11. 2020

These days, the  Portorož Business Conference, the central economic conference in the region, is  taking place. This year’s focus theme is the flexibility and resilience of the  economy. The President of the  Board of Management of Lek and the Novartis Country President Slovenia, Robert  Ljoljo, presented the operation of Novartis in Slovenia during the pandemic at  a round table entitled New Business Models on the Test of Flexibility and  Resilience - How Fast and Resilient are our Companies.

Participants in the round table discussed, from the perspective of various business sectors, their own experiences with tackling the pandemic and how other Slovenian companies can transfer good practices to their business. Robert Ljoljo presented in particular the importance of advance preparedness for crisis situations, such as the Novartis Emergency Management system (NEM), and high levels of agility of the company and employees.

 “Although we are among the companies whose operation is essential for the state and society, nothing was taken for granted in maintaing our smooth operations. At Novartis, we are constantly preparing for potential crisis situations, replaying possible scenarios and testing our response. Even before it was clear that Europe and Slovenia would be severely affected by the coronavirus, we were fully prepared in our company. Of great importance in the response was our agile culture, which allows us to adapt to different situations, and the unbossed culture which we foster at Novartis. Part of our success for smooth operation was certainly the high level of digitization, which we have been striving for in the last few years, “Ljoljo pointed out, among other things.

Prior to the commencement of the conference, the President of the Board of Management also met with IMB students at the Faculty of Economics at the virtual Novartis NetPoint and presented them with career opportunities at Novartis in Slovenia.